Spark Therapeutics

Dyno, Roche to tackle CNS, liver disease in gene therapy deal worth up to $1.8B
Dyno, Roche to tackle CNS, liver disease in gene therapy deal worth up to $1.8B
Fierce Biotech
Dyno
Roche
Spark Therapeutics
gene therapy
liver disease
CNS
Flag link:
Roche targets 2021 start for hemophilia A gene therapy phase 3 as optimization effort drags on
Roche targets 2021 start for hemophilia A gene therapy phase 3 as optimization effort drags on
Fierce Biotech
Roche
hemophilia A
Spark Therapeutics
SPK-8011
Flag link:
Spark touts animal data for a solution to AAV gene therapy's antibody problem
Spark touts animal data for a solution to AAV gene therapy's antibody problem
Endpoints
Spark Therapeutics
AAV gene therapy
Flag link:
Spark, Ipsen and more join advocacy groups, agencies in Rare Disease Day 2020 efforts
Spark, Ipsen and more join advocacy groups, agencies in Rare Disease Day 2020 efforts
Fierce Pharma
Spark Therapeutics
Ipsen
Rare Diseases
Flag link:
Roche's digital partnerships flourish under live-and-let-live approach
Roche's digital partnerships flourish under live-and-let-live approach
Fierce Pharma
Roche
digital pharma
Spark Therapeutics
Flag link:
Top Biopharma M&As in 2019
Top Biopharma M&As in 2019
BioSpace
M&A
Bristol-Myers Squibb
Celgene
AbbVie
Allergan
Roche
Spark Therapeutics
Novartis
The Medicines Company
Alkermes
Rodin Therapeutics
Sumitomo Dainippon
Roivant
Flag link:
Roche's $4.8B deal for Spark cleared by FTC after long delay
Roche's $4.8B deal for Spark cleared by FTC after long delay
Biopharma Dive
Roche
Spark Therapeutics
M&A
FTC
Flag link:
Could Spark Therapeutics’ merger with Roche finally get the go-ahead?
Could Spark Therapeutics’ merger with Roche finally get the go-ahead?
Pharmaforum
Spark Therapeutics
Roche
UK
M&A
CMA
Flag link:
Roche extends tender offer for Spark Therapeutics, again
Roche extends tender offer for Spark Therapeutics, again
Marketwatch
Roche
Spark Therapeutics
M&A
Flag link:
Disruptor of the Year: The Federal Trade Commission
Disruptor of the Year: The Federal Trade Commission
Biopharma Dive
FTC
M&A
Roche
Spark Therapeutics
Flag link:
Put on hold music: Roche delays Spark buyout for the 9th — and quite possibly not the last — time
Put on hold music: Roche delays Spark buyout for the 9th — and quite possibly not the last — time
Endpoints
Roche
M&A
Spark Therapeutics
Flag link:
Why Roche's Acquisition Of Spark May Be Complete By Year's End
Why Roche's Acquisition Of Spark May Be Complete By Year's End
Investors Business Daily
Roche
Spark Therapeutics
M&A
Flag link:
With biosimilar threat under control (for now), Roche savors demand for its new drugs
With biosimilar threat under control (for now), Roche savors demand for its new drugs
Endpoints
Roche
M&A
Spark Therapeutics
China
Flag link:
Roche sets new deadline for Spark acquisition as divestiture speculation brews
Roche sets new deadline for Spark acquisition as divestiture speculation brews
Endpoints
Roche
Spark Therapeutics
M&A
Flag link:
Roche-Spark deal review in U.K. unnerves M&A watchers—and they were spooked already
Roche-Spark deal review in U.K. unnerves M&A watchers—and they were spooked already
Fierce Pharma
M&A
UK
Spark Therapeutics
Roche
antitrust
CMA
Flag link:
UK cost watchdog recommends Novartis' blindness therapy Luxturna
UK cost watchdog recommends Novartis' blindness therapy Luxturna
Yahoo/Reuters
Novartis
gene therapy
Luxturna
UK
NICE
Spark Therapeutics
Flag link:
Roche stays mum about FTC, CMA reviews as $4.3B Spark deal faces yet another delay. What's up?
Roche stays mum about FTC, CMA reviews as $4.3B Spark deal faces yet another delay. What's up?
Endpoints
Roche
Spark Therapeutics
FTC
CMA
M&A
Flag link:
The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate
The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate
Yahoo/Benzinga
biotech
earnings
Immunic
Alkermes
Conatus
Aevi Genomic
Tricida
Curis
Ultragenyx
Leap Therapeutics
Cidara Therapeutics
Akcea
Spark Therapeutics
Eli Lilly
AnaptysBio
clinical trials
Flag link:
Roche, Spark push back takeover deadline in $4.3 billion deal
Roche, Spark push back takeover deadline in $4.3 billion deal
Yahoo/Reuters
Roche
Pharma CEOs
Severin Schwan
M&A
Spark Therapeutics
Flag link:
Sangamo backs up early success for hemophilia gene therapy
Sangamo backs up early success for hemophilia gene therapy
Biopharma Dive
Sangamo
gene therapy
hemophilia A
SB-525
Pfizer
Spark Therapeutics
Biomarin
Flag link:

Pages